A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : anti-dsDNA / anti-double-stranded DNA

[Related PubMed/MEDLINE]
Total Number of Papers: 299
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   anti-dsDNA  (>> Co-occurring Abbreviation)
Long Form:   anti-double-stranded DNA
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. SLE
2021 Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. HDA, SLE, SRI
2021 Hereditary Chorea Associated With and Aggravated by Systemic Lupus Erythematosus. ANA, HD, PCR, SLE
2021 Lupus-like membranous nephropathy. Is it lupus? Report of 5 cases in a reference hospital in Mexico. ANA, SLE
2021 Predictors of renal flares and long-term renal outcome in patients with lupus nephritis: results from daily clinical practice. CKD, LN, UMCG
2021 Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt Licenses the Differentiation and Function of a Unique Subset of Follicular Helper T Cells in Response to Immunogenic Self-DNA in Systemic Lupus Erythematosus. ICOS, IL-17, RORgammat
2021 Serum levels of n-3 and n-6 polyunsaturated fatty acids in patients with systemic lupus erythematosus and their association with disease activity: a pilot study. ANA, EPA, LA, PUFAs, SLE, SLEDAI
2021 Systemic Lupus Erythematosus With Multi-Organ Involvement in a Young Female: Lymphadenopathy, Lupus Cerebritis, Lupus Nephritis, and Cardiac Manifestations. AMS, ANAs, LAP, SLE
2020 Angioimmunoblastic T-cell Lymphoma: A Mimic for Lupus. ANA, SLE
10  2020 Anti-C1q antibodies in lupus nephritis and their correlation with the disease activity. LN, SLE
11  2020 Appropriateness of laboratory tests in the diagnosis of inflammatory rheumatic diseases among patients newly referred to rheumatologists. ANA, ENA, RA, RF, SpA
12  2020 Association of Dietary Quality With Risk of Incident Systemic Lupus Erythematosus in the Nurses' Health Study and Nurses' Health Study II. aMed, DASH, EDIP, HRs, SLE
13  2020 Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study. SLE, SRI
14  2020 Blockade of anti-dsDNA ameliorates systemic lupus erythematosus in MRL/Faslpr mice through ameliorating inflammation via the PKCδ-NLRC4 axis. IL-1beta, MFI, PKCdelta, qRT-PCR, SLE
15  2020 Clinical and pathological characteristics of ANA/anti-dsDNA positive patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. AAV, ANA, ANCA, eGFR, ESRD
16  2020 DNA Vaccination With Hsp70 Protects Against Systemic Lupus Erythematosus in (NZB × NZW)F1 Mice. ---
17  2020 Factors affecting the Apgar score of offsprings born to mothers suffering from systemic lupus erythematosus. LLDAS, SLE, SLEDAI
18  2020 Low-Level Proteinuria in Systemic Lupus Erythematosus. ACR, AKI, LN, SLE, UPCR
19  2020 Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis. GFR, LN
20  2020 Peptidylarginine Deiminase 4 Promotes the Renal Infiltration of Neutrophils and Exacerbates the TLR7 Agonist-Induced Lupus Mice. IMQ, JLP, KO, MAPK, PAD4, TLR7, WT
21  2020 Pericardial Tumor, a Rare Manifestation of Sjogren's Syndrome Secondary to Systemic Lupus Erythematosus. ANA, PET, SLE
22  2020 Periodontitis is associated with disease severity and anti-double stranded DNA antibody and interferon-gamma levels in patients with systemic lupus erythematosus. IFN-gamma, PI, SLE, SLEDAI
23  2020 The protection of NF-κB inhibition on kidney injury of systemic lupus erythematosus mice may be correlated with lncRNA TUG1. ANA, NF-kappaB, SLE
24  2019 alpha-mangostin attenuates pristane-induced lupus nephritis by regulating Th17 differentiation. anti-IgG, IFN, IL, LN, RORgammat, Th17
25  2019 Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. SLE
26  2019 Cerebral blood flow abnormalities in neuropsychiatric systemic lupus erythematosus. aCL, NPSLE
27  2019 Clinical Characteristics of Hydralazine-induced Lupus. ANA, MPO, PR3
28  2019 Clinical manifestations, immunological features and prognosis of Chinese pediatric systemic lupus erythematosus: A single-center study. anti-SSA, LN, pSLE
29  2019 Coordination between innate immune cells, type I IFNs and IRF5 drives SLE pathogenesis. anti-RBP, IFN, IRF5, NETs, pDCs, SLE
30  2019 Correlation between Osteoprotegerin Levels and Antiphospholipid Syndrome Parameters. aPLs, APS, OPG, SLE
31  2019 Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis. CI, IT, LN, ORR, RR, SLE-DAI
32  2019 Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus. SLE
33  2019 Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. CH50, SLE
34  2019 First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. EOT, TEAEs
35  2019 Gut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosus. ELISA, FMT, NGS, qRT-PCR, SLE
36  2019 Impact of extractable nuclear antigen, anti-double stranded DNA, antiphospholipid antibody, and anticardiolipin antibody positivity on obstetrical complications and pregnancy outcomes. aCL, aPL, BOIp, ENA
37  2019 Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice. DZNep, IL-10
38  2019 Interleukin-32gamma: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus. IL, LN, SLE
39  2019 Overlap Syndrome Involving Systemic Lupus Erythematosus and Autoimmune Hepatitis in Children: A Case Report and Literature Review. AIH, PBC, PSC, SLE
40  2019 Pattern of antinuclear antibody and antiextractable nuclear antigen antibody test requisitions in Riyadh. ANA, KKUH, SARD
41  2019 Pim-1 as a Therapeutic Target in Lupus Nephritis. LN, PBMCs, siRNA, SLE
42  2019 Role of anti-DNA auto-antibodies as biomarkers of response to treatment in systemic lupus erythematosus patients: hypes and hopes. Insights and implications from a comprehensive review of the literature. SLE
43  2018 Allergy inhibitory receptor-1 inhibits autoantibody production via upregulation of apoptotic debris clearance by macrophages. Allergin-1, IgG, WT
44  2018 Amelioration of regulatory T cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in pristane-induced lupus mice model. ANA, anti-RNP, FOXP3, IL-6, SLE
45  2018 Anti-Double-Stranded DNA Isotypes and Anti-C1q Antibody Improve the Diagnostic Specificity of Systemic Lupus Erythematosus. Ig, SLE
46  2018 Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity. SLE
47  2018 Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials. ANA, TNFi
48  2018 Combined utilization of untimed single urine of MCP-1 and TWEAK as a potential indicator for proteinuria in lupus nephritis: A case-control study. 24hr UP, BUN, Cr, CysC, HCs, LN, ROC, SLE, TNF, uACR, uMCP-1
49  2018 Dysregulated heme oxygenase-1low M2-like macrophages augment lupus nephritis via Bach1 induced by type I interferons. HO, IL, LN
50  2018 Effect of active immunization with IL-17A on B cell functionand infection risk in pristane-induced lupus model. IL, KLH, MRSA
51  2018 Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. AEs, ITT, s.c, SLE, SRI-4
52  2018 Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). AIH, ALBIA, AUROC, CLIFT, HK-1, KLHL-12, LIA, PBC, PBC-AIH OS, PBC-AIH OS
53  2018 In vivo study: Th1-Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics. ANA, anti-RNP, CTL, IFN-gamma, IL-17, RORgammat, SLE
54  2018 Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness, autoimmunity, metabolic syndrome and cortisol levels. ANA, MetS, PAI-1, PECAM-1, SLE, SLEDAI, VCAM-1
55  2018 iRhom2 promotes lupus nephritis through TNF-alpha and EGFR signaling. ADAM17, HB-EGF, iRhom2, LN
56  2018 Micelle-Forming Dexamethasone Prodrug Attenuates Nephritis in Lupus-Prone Mice without Apparent Glucocorticoid Side Effects. Dex, GCs, LN
57  2018 Pediatric systemic lupus erythematosus. Retrospective analysis of clinico-laboratory parameters and their association with Systemic Lupus Erythematosus Disease Activity Index score. ANA, LE, pSLE, SLEDAI
58  2018 Procyanidin B2 prevents lupus nephritis development in mice by inhibiting NLRP3 inflammasome activation. LN, PCB2, SLE
59  2018 Sophocarpine attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kappaB activation. LN, SLE
60  2018 Therapeutic effect of human amniotic epithelial cells in murine models of Hashimoto's thyroiditis and Systemic lupus erythematosus. ANAs, EAT, hAECs, HT, pTg, SLE, TgAb, TPOAb, TSH
61  2018 Transplantation of adipose tissue-derived stem cells ameliorates autoimmune pathogenesis in MRL/lpr mice : Modulation of the balance between Th17 and Treg. ADSCs, MSCs
62  2018 Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis. ACR, AUC, CXCL4, SLE, SLEDAI, VCAM-1
63  2017 Aconitine: A potential novel treatment for systemic lupus erythematosus. ---
64  2017 Association of anti-CLIC2 and anti-HMGB1 autoantibodies with higher disease activity in systemic lupus erythematosus patients. ANA, anti-CLIC2, anti-HMGB1, CRP, SLE, SLEDAI
65  2017 Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients. CRT, HC, SLE
66  2017 Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity. BZ, CYC, PBS, SLE
67  2017 Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis. CsA, CYC, MMF, SLE
68  2017 Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era. AAbs, aCL, ANAs, ANCAs, anti-beta2GP1, HAART, IgG
69  2017 Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. ---
70  2017 Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-gamma monoclonal antibody, in SLE subjects without or with lupus nephritis. AEs, IFN, LN
71  2017 Serum Th1 and Th17 related cytokines and autoantibodies in patients with Posner-Schlossman syndrome. ACA, AKA, ANA, ANCA, GPI, IFN-gamma, IL-1beta, PSS, TNF-alpha
72  2017 T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients. IgG, SLE
73  2017 The Potent Inhibitory Effect of beta-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis. CRP, RA, RF
74  2017 What Can We Do When All Collapses? Fatal Outcome of Collapsing Glomerulopathy and Systemic Lupus Erythematosus With Diffuse Alveolar Hemorrhage: Case Report. ANA, ANCAs, CG, DAH, HBV, HCV, HIV, SLE
75  2016 Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus. IGFBP-2, PGA, SLE, SLEDAI, TNFRII
76  2016 Depression, Anxiety and Disease-Related Variables and Quality of Life Among Individuals With Systemic Lupus Erythematosus Living in Kermanshah Province, Iran. ANA, anti-Sm, GH, HRQoL, PCS, PF, SF, SLE
77  2016 Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. CLASI, DAS28, SLE
78  2016 Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. IFN, SLE
79  2016 Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine. ANA, AZA, c-ANCA, ECCO, HIV, IBD, p-ANCA, PG, UC
80  2016 Inhibition of G Protein betagamma Subunit Signaling Abrogates Nephritis in Lupus-Prone Mice. GC, SLE
81  2016 JAK3-STAT pathway blocking benefits in experimental lupus nephritis. IgG, JAK-STAT, LN
82  2016 No significant effects of Poly(I:C) on human umbilical cord-derived mesenchymal stem cells in the treatment of B6.MRL-Fas(lpr) mice. IgG, P-MSC
83  2016 Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins. MMF, SLE
84  2016 Prevalence of positive autoimmune biomarkers in the brucellosis patients. ANA, RF
85  2016 Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice. BUN, Cr, HLJDD, IFN-gamma, IHC, IL-10, IL-6, LN, pSTAT3, WB
86  2016 Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years. BILAG, RTX, SLE
87  2015 Analysis of the Humoral Immune Response to Human Leukocyte Antigens in Turkish Renal Transplant Candidates and Relationship Between Autoimmune Disorders. ANA, anti-Tg, anti-TPO, HLA, SLE
88  2015 Autoantibodies in the sera of breast cancer patients: Antinuclear and anti-double stranded DNA antibodies as example. ADSDAs, ANAs, ELISA, RICK, SD
89  2015 Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab. AEs, BLyS, CRP, SLE, SRI
90  2015 Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis. ALD-DNA, HMGB1, SLE
91  2015 Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. ALMS, CR, eGFR, IVC, TF
92  2015 Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. ELISPOT, LLPCs, SLE
93  2015 MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19. ASCs, hCD19, Tg
94  2015 Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin. IFN, mtDNA, NETs, pDCs, PMA, SLE
95  2015 Novel Autoantigens Associated with Lupus Nephritis. IC, LN, RRP8, SLE, TNP1
96  2015 Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. HRCT, LN, SLE
97  2015 Successful Detection of Renal Involvement in Sjogren's Syndrome Secondary to Systemic Lupus Erythematosus by Renal Biopsy. SLE
98  2015 The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. IFN, PC, SLE
99  2015 The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis. TDP1, topo I
100  2014 Autoantibody detection: prevailing practices at a tertiary care hospital in Riyadh. ANA, ANCA, ENA, RF